Display options
Cite
McMaster KS, Chatterjee T, McBrayer D, et al. Thrombolytic use in the region around Amarillo, Texas, in patients with ST elevation myocardial infarction. Proc (Bayl Univ Med Cent). 2018;31(1):9-11doi: 10.1080/08998280.2017.1400877.
McMaster, K. S., Chatterjee, T., McBrayer, D., & Brabham, D. (2018). Thrombolytic use in the region around Amarillo, Texas, in patients with ST elevation myocardial infarction. Proceedings (Baylor University. Medical Center), 31(1), 9-11. https://doi.org/10.1080/08998280.2017.1400877
McMaster, Kelly S, et al. "Thrombolytic use in the region around Amarillo, Texas, in patients with ST elevation myocardial infarction." Proceedings (Baylor University. Medical Center) vol. 31,1 (2018): 9-11. doi: https://doi.org/10.1080/08998280.2017.1400877
McMaster KS, Chatterjee T, McBrayer D, Brabham D. Thrombolytic use in the region around Amarillo, Texas, in patients with ST elevation myocardial infarction. Proc (Bayl Univ Med Cent). 2018 Feb 01;31(1):9-11. doi: 10.1080/08998280.2017.1400877. eCollection 2018 Jan. PMID: 29686544; PMCID: PMC5903524.
Copy Download .nbib Format: NLM
Share it on

Proc (Bayl Univ Med Cent). 2018 Feb 01;31(1):9-11. doi: 10.1080/08998280.2017.1400877. eCollection 2018 Jan.

Thrombolytic use in the region around Amarillo, Texas, in patients with ST elevation myocardial infarction.

Proceedings (Baylor University. Medical Center)

Kelly S McMaster, Totini Chatterjee, Drew McBrayer, David Brabham

Affiliations

  1. Department of Internal Medicine, Texas Tech University Health Sciences Center School of Medicine-Amarillo, Amarillo, Texas.
  2. Department of Internal Medicine, Cardiology Center of Amarillo and Texas Tech University Health Sciences Center School of Medicine-Amarillo, Amarillo, Texas.

PMID: 29686544 PMCID: PMC5903524 DOI: 10.1080/08998280.2017.1400877

Abstract

Appropriate administration of thrombolytic therapy is particularly important for ST elevation myocardial infarction (STEMI) patients who are unable to access primary percutaneous coronary intervention (PCI) in a timely manner. We evaluated the current state of thrombolytic therapy in the Panhandle region of West Texas where access to primary PCI is poor. The medical records of 79 patients transferred from 20 outlying facilities to the two hospitals in Amarillo, Texas, for STEMI in 2016 were retrospectively evaluated for time of onset of chest pain, initial electrocardiogram findings, medication reconciliation, and any contraindications to thrombolytic therapy. Medical record review allowed the patients to be sorted into one of five predefined categories based on our findings. The most common error discovered was failure to deliver the appropriate accompanying medications with thrombolytic therapy, noted in 43% of patients. Other errors included failure to deliver thrombolytic therapy in patients who met no clear contraindications to thrombolytic therapy (21%) and administering thrombolytic therapy to patients who had not suffered STEMI (4%). Thirteen percent of patients were appropriately treated with thrombolytic therapy and 19% of patients met a contraindication to thrombolytic therapy and were not treated with thrombolytic therapy, as was appropriate.

Keywords: Acute coronary syndrome; ST-elevation myocardial infarction; dual antiplatelet therapy; thrombolytic therapy

References

  1. N Engl J Med. 2005 Mar 24;352(12):1179-89 - PubMed
  2. Am Heart J. 2005 Feb;149(2):227-33 - PubMed
  3. Circulation. 2012 Oct 16;126(16):2020-35 - PubMed
  4. J Am Coll Cardiol. 2013 Jan 29;61(4):e78-e140 - PubMed
  5. S D Med. 2013 Sep;66(9):366-9 - PubMed
  6. J Am Coll Cardiol. 1989 Oct;14(4):1085-92 - PubMed
  7. Lancet. 1994 Feb 5;343(8893):311-22 - PubMed
  8. BMJ. 1996 Sep 14;313(7058):652-9 - PubMed

Publication Types